Noxxon Attains Milestone In Drug Discovery Partnership With Lilly

Noxxon Pharma, developing medicines based on its proprietary Spiegelmer technology, has achieved an important milestone in its drug discovery and development partnership with Eli Lilly and Company.

Noxxon’s successful identification of a Spiegelmer with picomolar affinity and high selectivity for its target met contractually specified milestone criteria and triggers a payment of an undisclosed amount. Lilly and Noxxon have entered into the agreement last year to discover and develop Spiegelmers for the treatment of migraine.

Following the completion of the discovery work, the identified Spiegelmer will undergo pharmacological testing and pre-clinical development. Lilly is responsible for the pre-clinical and clinical development as well as the commercialisation of the Spiegelmer product, provided the product is approved by regulatory authorities.

Sven Klussmann, chief scientific officer of Noxxon, said: “The rapid delivery of what appears to be an immensely potent compound illustrates the power of the Spiegelmer platform and represents the first major landmark in our partnership. We look forward to Lilly applying its substantial expertise in the field of migraine in taking the Spiegelmer to the next level.”

William Chin, vice president of discovery and clinical research at Lilly, said: “Noxxon’s identification of the lead compound is an outstanding milestone achievement. The use of Spiegelmers for the potential treatment of migraine headache is a promising approach. We are excited to continue our work with Noxxon to bring Spiegelmers to our patients as soon as possible.”